Streetbeat News

ABIO

ARCA biopharma, Inc.

https://www.arcabio.com

Industry

Biotechnology

ARCA biopharma, Inc., a clinical-stage biopharmaceutical company, develops and commercializes genetically targeted therapies for cardiovascular diseases. Its lead product candidates are Recombinant Nematode Anticoagulant Protein c2 (rNAPc2) (AB201), which is in Phase IIb clinical trial for the treatment for COVID-19; and Gencaro (bucindolol hydrochloride), a pharmacogenetically-targeted beta-adrenergic receptor antagonist that has completed Phase IIb trial for the treatment of atrial fibrillation in patients with chronic heart failure. ARCA biopharma, Inc. has a collaboration agreement with LabCorp to develop genetic test for GENETIC-AF clinical trial; and research collaboration with Colorado Prevention Center, the University of Colorado's Academic Research Organization to develop and commercialize Gencaro. The company was incorporated in 2004 and is headquartered in Westminster, Colorado.

Open

2.35

Mkt cap

35M

Volume

291K

High

28.80

P/E Ratio

-4.90

52-wk high

53.88

Low

2.25

Div yield

0.73

52-wk low

2.25

Oruka Therapeutics has completed its merger with ARCA Biopharma and will begin trading under the ticker ORKA. The company also appointed CRISPR CEO Samarth Kulkarni as Chairman. A $275 million private placement was completed, and the company has approximately 46.3 million shares outstanding.

Portfolio Pulse from Benzinga Newsdesk

September 03, 2024 | 11:06 am

Trading for ABIO has been halted as of 7:50:00 p.m. ET due to pending news. Investors should stay alert for updates that could impact the stock's price.

Portfolio Pulse from Benzinga Newsdesk

August 30, 2024 | 11:50 pm

Affirm Holdings, Inc. (AFRM) shares surged 18% in pre-market trading due to better-than-expected Q4 earnings and positive Q1 guidance. Other notable pre-market movers include BioCardia, Inc. (BCDA) with a 109.5% gain after FDA clearance, and Big Lots, Inc. (BIG) with a 30.5% decline amid bankruptcy concerns.

Portfolio Pulse from Avi Kapoor

August 29, 2024 | 9:37 am

ARCA Biopharma has updated its special dividend to $1.613 per share in preparation for its merger with Oruka Therapeutics. The dividend will be paid on August 28, 2024, to shareholders of record as of August 26, 2024.

Portfolio Pulse from Benzinga Newsdesk

August 27, 2024 | 7:30 am

ARCA Biopharma's shares fell following the announcement of a 1-for-12 reverse stock split as part of its proposed merger with Oruka Therapeutics.

Portfolio Pulse from Benzinga Newsdesk

August 26, 2024 | 3:14 pm

ARCA biopharma has announced a 1-for-12 reverse stock split in preparation for its merger with Oruka Therapeutics. The stock will trade under the new symbol 'ORKA' on Nasdaq starting September 3, 2024.

Portfolio Pulse from Benzinga Newsdesk

August 23, 2024 | 8:31 pm

ARCA Biopharma Inc (NASDAQ:ABIO) shares rose by 12.5% following the announcement of a special dividend of $1.59 per share related to its merger with Oruka Therapeutics. The dividend is contingent on shareholder approval of the merger, with key dates set for August 22 and August 29.

Portfolio Pulse from Henry Khederian

August 19, 2024 | 2:28 pm

ARCA Biopharma shares rose following the announcement of a special dividend of $1.59 per share.

Portfolio Pulse from Benzinga Newsdesk

August 19, 2024 | 1:59 pm

U.S. stock futures are trading lower this Monday morning. Key stocks to watch include Estée Lauder (EL), ZIM Integrated Shipping (ZIM), ARCA Biopharma (ABIO), Fabrinet (FN), and Palo Alto Networks (PANW). Estée Lauder and ZIM Integrated Shipping are set to release earnings before the market opens, while Fabrinet and Palo Alto Networks will report after the closing bell. ARCA Biopharma announced a special dividend.

Portfolio Pulse from Avi Kapoor

August 19, 2024 | 7:47 am

ARCA Biopharma shares are trading higher after the company announced a special dividend of $1.59 per share.

Portfolio Pulse from Benzinga Newsdesk

August 16, 2024 | 8:37 pm

All corporate logos and prices are for illustrative purposes only and are not a recommendation, an offer to sell, or a solicitation of an offer to buy any security.